Paul Hudson, Getty Images
December 2, 2019 08:08 AM ESTUpdated 11:27 AM
R&D

Just days ahead of his big strate­gic re­veal, Sanofi CEO Paul Hud­son lines up a $350M sale

John Carroll

Editor & Founder

We won’t find out ex­act­ly what Paul Hud­son wants to fo­cus on in build­ing the fu­ture at Sanofi for an­oth­er 8 days, when he’s promised the big re­veal. But chances are what­ev­er he plans to con­cen­trate on, it won’t be the sur­gi­cal prod­ucts group at Seprafilm.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Af­ter eight years with Sanofi, Frank Nes­tle de­parts as CSO, glob­al head of re­search

Pa­tient dies in Pfiz­er’s Phase 2 Duchenne mus­cu­lar dy­s­tro­phy tri­al

'Big­ger, faster, bet­ter': Iso­mor­phic, Deep­Mind un­veil Al­phaFold 3, go­ing be­yond pro­tein pre­dic­tions

Af­ter CRISPR ba­by scan­dal shut down work for years, Chi­na gene edit­ing com­pa­nies are restart­ing clin­i­cal tri­als

Mar­i­nus lays off 20% of work­force, cuts costs to stay afloat

sponsored

Med­ical Af­fairs: The Crit­i­cal Link Be­tween Sci­ence, Physi­cians and Pa­tients

A service from the Financial Times